These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 38136369

  • 1. Diagnostic Performance of 99mTc-iPSMA SPECT/CT in the Initial Staging of Patients with Unfavorable Intermediate-, High-, and Very High-Risk Prostate Cancer: A Comparative Analysis with 18F-PSMA-1007 PET/CT.
    Vargas-Ahumada JE, González-Rueda SD, Sinisterra-Solís FA, Casanova-Triviño P, Pitalúa-Cortés Q, Soldevilla-Gallardo I, Scavuzzo A, Jimenez-Ríos MA, García-Pérez FO.
    Cancers (Basel); 2023 Dec 13; 15(24):. PubMed ID: 38136369
    [Abstract] [Full Text] [Related]

  • 2. Head to head comparison performance of 99mTc-EDDA/HYNIC-iPSMA SPECT/CT and 68Ga-PSMA-11 PET/CT a prospective study in biochemical recurrence prostate cancer patients.
    García-Pérez FO, Davanzo J, López-Buenrostro S, Santos-Cuevas C, Ferro-Flores G, Jímenez-Ríos MA, Scavuzzo A, Santana-Ríos Z, Medina-Ornelas S.
    Am J Nucl Med Mol Imaging; 2018 Dec 13; 8(5):332-340. PubMed ID: 30510850
    [Abstract] [Full Text] [Related]

  • 3. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 Dec 13; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 4. Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT/CT in prostate carcinoma: A comparative analysis with Ga-68 PSMA PET/CT.
    Lawal IO, Ankrah AO, Mokgoro NP, Vorster M, Maes A, Sathekge MM.
    Prostate; 2017 Aug 13; 77(11):1205-1212. PubMed ID: 28649735
    [Abstract] [Full Text] [Related]

  • 5. Clinical translation of a PSMA inhibitor for 99mTc-based SPECT.
    Ferro-Flores G, Luna-Gutiérrez M, Ocampo-García B, Santos-Cuevas C, Azorín-Vega E, Jiménez-Mancilla N, Orocio-Rodríguez E, Davanzo J, García-Pérez FO.
    Nucl Med Biol; 2017 May 13; 48():36-44. PubMed ID: 28193503
    [Abstract] [Full Text] [Related]

  • 6. A Prospective Comparison of 18F-prostate-specific Membrane Antigen-1007 Positron Emission Tomography Computed Tomography, Whole-body 1.5 T Magnetic Resonance Imaging with Diffusion-weighted Imaging, and Single-photon Emission Computed Tomography/Computed Tomography with Traditional Imaging in Primary Distant Metastasis Staging of Prostate Cancer (PROSTAGE).
    Anttinen M, Ettala O, Malaspina S, Jambor I, Sandell M, Kajander S, Rinta-Kiikka I, Schildt J, Saukko E, Rautio P, Timonen KL, Matikainen T, Noponen T, Saunavaara J, Löyttyniemi E, Taimen P, Kemppainen J, Dean PB, Blanco Sequeiros R, Aronen HJ, Seppänen M, Boström PJ.
    Eur Urol Oncol; 2021 Aug 13; 4(4):635-644. PubMed ID: 32675047
    [Abstract] [Full Text] [Related]

  • 7. The Theranostic Optimization of PSMA-GCK01 Does Not Compromise the Imaging Characteristics of [99mTc]Tc-PSMA-GCK01 Compared to Dedicated Diagnostic [99mTc]Tc-EDDA/HYNIC-iPSMA in Prostate Cancer.
    Mamlins E, Scharbert L, Cardinale J, Krotov M, Winter E, Rathke H, Strodel B, Ankrah AO, Sathekge M, Haberkorn U, Kratochwil C, Giesel FL.
    Mol Imaging Biol; 2024 Feb 13; 26(1):81-89. PubMed ID: 38066252
    [Abstract] [Full Text] [Related]

  • 8. [99cmTc]Tc-PSMA-I&S-SPECT/CT: experience in prostate cancer imaging in an outpatient center.
    Werner P, Neumann C, Eiber M, Wester HJ, Schottelius M.
    EJNMMI Res; 2020 May 07; 10(1):45. PubMed ID: 32382945
    [Abstract] [Full Text] [Related]

  • 9. An Analysis of the Diagnostic Performance of Tc-99m PSMA SSPECT/CT in Biochemically Recurrent Prostate Cancer Compared with Ga-68 PSMA PET/CT: A Single-center, Prospective Study.
    Ora M, Saini VK, Dixit M, Singh UP, Gambhir S.
    Indian J Nucl Med; 2024 May 07; 39(3):170-176. PubMed ID: 39291065
    [Abstract] [Full Text] [Related]

  • 10. Head-to-head comparison of 99mTc-PSMA and 99mTc-MDP SPECT/CT in diagnosing prostate cancer bone metastasis: a prospective, comparative imaging trial.
    Zhang Y, Lin Z, Li T, Wei Y, Yu M, Ye L, Cai Y, Yang S, Zhang Y, Shi Y, Chen W.
    Sci Rep; 2022 Sep 26; 12(1):15993. PubMed ID: 36163353
    [Abstract] [Full Text] [Related]

  • 11. [99mTc]Tc-HYNIC-ALUG SPECT/CT in the initial staging of 227 consecutive patients with newly diagnosed prostate cancer: a 5-year monocentric retrospective study.
    Li B, Ding X, Duan L, Shi J, Tang M, Zhang J, Zhao Z, Wu X, Gao Y.
    Front Endocrinol (Lausanne); 2024 Sep 26; 15():1326858. PubMed ID: 38449842
    [Abstract] [Full Text] [Related]

  • 12. Direct comparison of 99mTc-PSMA SPECT/CT and 68Ga-PSMA PET/CT in patients with prostate cancer.
    Albalooshi B, Al Sharhan M, Bagheri F, Miyanath S, Ray B, Muhasin M, Zakavi SR.
    Asia Ocean J Nucl Med Biol; 2020 Sep 26; 8(1):1-7. PubMed ID: 32064277
    [Abstract] [Full Text] [Related]

  • 13. Comparison of hybrid 68Ga-PSMA-PET/CT and 99mTc-DPD-SPECT/CT for the detection of bone metastases in prostate cancer patients: Additional value of morphologic information from low dose CT.
    Janssen JC, Meißner S, Woythal N, Prasad V, Brenner W, Diederichs G, Hamm B, Makowski MR.
    Eur Radiol; 2018 Feb 26; 28(2):610-619. PubMed ID: 28779400
    [Abstract] [Full Text] [Related]

  • 14. 99mTc-labeled PSMA inhibitor: Biokinetics and radiation dosimetry in healthy subjects and imaging of prostate cancer tumors in patients.
    Santos-Cuevas C, Davanzo J, Ferro-Flores G, García-Pérez FO, Ocampo-García B, Ignacio-Alvarez E, Gómez-Argumosa E, Pedraza-López M.
    Nucl Med Biol; 2017 Sep 26; 52():1-6. PubMed ID: 28575794
    [Abstract] [Full Text] [Related]

  • 15. A prospective intra-individual comparison of [68Ga]Ga-PSMA-11 PET/CT, [68Ga]Ga-NODAGAZOL PET/CT, and [99mTc]Tc-MDP bone scintigraphy for radionuclide imaging of prostate cancer skeletal metastases.
    Lawal IO, Mokoala KMG, Mahapane J, Kleyhans J, Meckel M, Vorster M, Ebenhan T, Rösch F, Sathekge MM.
    Eur J Nucl Med Mol Imaging; 2021 Jan 26; 48(1):134-142. PubMed ID: 32424485
    [Abstract] [Full Text] [Related]

  • 16. Delayed Imaging Improves Lesion Detectability in [99mTc]Tc-PSMA-I&S SPECT/CT in Recurrent Prostate Cancer.
    Berliner C, Steinhelfer L, Chantadisai M, Kroenke M, Koehler D, Pose R, Bannas P, Knipper S, Eiber M, Maurer T.
    J Nucl Med; 2023 Jul 26; 64(7):1036-1042. PubMed ID: 37230531
    [Abstract] [Full Text] [Related]

  • 17. Comparing the role of 99m Tc-HYNIC-PSMA-11 and 99m Tc-MDP scintigraphy for the initial staging of intermediate to high-risk prostate cancer.
    Ghaedian T, Abdinejad M, Nasrollahi H, Ghaedian M, Firuzyar T.
    Nucl Med Commun; 2023 Oct 01; 44(10):864-869. PubMed ID: 37464793
    [Abstract] [Full Text] [Related]

  • 18. Diagnostic value of [99mTc]Tc-PSMA-I&S-SPECT/CT for the primary staging and restaging of prostate cancer.
    Farkas I, Sipka G, Bakos A, Maráz A, Bajory Z, Mikó Z, Czékus T, Urbán S, Varga L, Pávics L, Besenyi Z.
    Ther Adv Med Oncol; 2024 Oct 01; 16():17588359231221342. PubMed ID: 38249326
    [Abstract] [Full Text] [Related]

  • 19. 99mTc-PSMA targeted robot-assisted radioguided surgery during radical prostatectomy and extended lymph node dissection of prostate cancer patients.
    Yılmaz B, Şahin S, Ergül N, Çolakoğlu Y, Baytekin HF, Sökmen D, Tuğcu V, Taşçı Aİ, Çermik TF.
    Ann Nucl Med; 2022 Jul 01; 36(7):597-609. PubMed ID: 35426599
    [Abstract] [Full Text] [Related]

  • 20. Relationship between PSA kinetics and Tc-99m HYNIC PSMA SPECT/CT detection rates of biochemical recurrence in patients with prostate cancer after radical prostatectomy.
    Liu C, Zhu Y, Su H, Xu X, Zhang Y, Ye D, Hu S.
    Prostate; 2018 Dec 01; 78(16):1215-1221. PubMed ID: 30027591
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.